Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to -$42.0 million.

  • Genmab A's Net Cash Flow rose 9741.38% to -$42.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $332.0 million, marking a year-over-year increase of 11140.11%. This contributed to the annual value of $332.0 million for FY2025, which is 13742.95% up from last year.
  • Latest data reveals that Genmab A reported Net Cash Flow of -$42.0 million as of Q4 2025, which was up 9741.38% from $461.0 million recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Net Cash Flow peaked at $461.0 million during Q3 2025, and registered a low of -$4.9 billion during Q4 2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$76.0 million (2024), whereas its average is -$832.3 million.
  • The largest annual percentage gain for Genmab A's Net Cash Flow in the last 5 years was 40394.74% (2025), contrasted with its biggest fall of 6523.3% (2025).
  • Genmab A's Net Cash Flow (Quarter) stood at -$4.9 billion in 2023, then surged by 66.93% to -$1.6 billion in 2024, then surged by 97.41% to -$42.0 million in 2025.
  • Its last three reported values are -$42.0 million in Q4 2025, $461.0 million for Q3 2025, and -$318.0 million during Q2 2025.